Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just in the past year. Several more are nearing launch, including BMS’s Zeposia and Novartis’s ofatumumab, sustaining a rapid pace of change in the MS market. Developers of both current and emerging DMTs must continually reassess their products’ level of differentiation and likely future role in this continually evolving and highly competitive space. This report will explore neurologists’ perceptions of established and newly launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as more DMTs expand—and further complicate—prescribers’ choice.
- How are different MS subpopulations (i.e., clinically isolated syndrome, relapsing-remitting, secondary-progressive, and primary-progressive) treated today?
- How do product shares differ across lines of therapy? Are high-efficacy therapies (e.g., Ocrevus) factoring more into early-line treatment decisions?
- How has neurologists’ prescribing changed in the past year, and why? What further changes do they expect within the next year?
- What are neurologists’ opinions on the newest entrants in the MS market, and how are they incorporating these DMTs in the treatment paradigm?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets Covered: United States
Primary research: Survey of 94 U.S. neurologists
Key drugs covered: Aubagio, glatiramer acetate, Gilenya, interferons, Lemtrada, Mavenclad, Mayzent, Ocrevus, ofatumumab, Tecfidera, Tysabri, Vumerity, Zeposia
Key companies: Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Roche, Sanofi Genzyme
Key insights provided:
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician insight on persistency and compliance
- Physician-reported recent/anticipated changes in brand usage or treatment approach
- Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)
Author(s): Bethany Christmann, PhD
Bethany Christmann, Ph.D., has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her Ph.D. in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.